Vitamin B‑Complex Supplementation in End‑Stage Kidney Disease (CKD Stage 5)

Safety Overview

In patients with CKD stage 5, vitamin B‑complex tablets are considered safe when prescribed for a documented deficiency or proven inadequate dietary intake; routine supplementation for cardiovascular risk reduction is not recommended. KDOQI (Kidney Disease Outcomes Quality Initiative) assigns a strong 1A recommendation against indiscriminate use. 1

Documented folate or vitamin B12 deficiency – Initiating B‑complex supplementation is reasonable when laboratory testing confirms low folate or B12 levels, accompanied by compatible clinical signs or symptoms. (Renal patients) 1
Inadequate dietary intake in dialysis‑dependent patients (CKD 5D) – Providing a multivitamin that includes water‑soluble B vitamins is appropriate to prevent micronutrient deficiencies when sustained dietary intake is insufficient. (Dialysis population) 3
Dialysis‑related losses – Hemodialysis and hemodiafiltration remove significant amounts of water‑soluble vitamins each session: approximately 4 mg thiamine, 0.3 mg folate, and 68 mg vitamin C are lost in the effluent. (Dialysis patients) 4

Routine supplementation for hyperhomocysteinemia – The KDOQI guideline issues a strong 1A recommendation against routine folate or B‑complex supplementation aimed at lowering cardiovascular events in CKD 3‑5D patients with elevated homocysteine, as no cardiovascular benefit has been demonstrated. (CKD 3‑5D) 1

Dietary and vitamin status evaluation – Periodic assessment by a renal dietitian should be performed to identify patients at risk for deficiency before initiating therapy. (All CKD 5 patients) 1
Laboratory confirmation of deficiency – Prior to prescribing, obtain serum folate, vitamin B12, and thiamine levels to verify deficiency. (CKD 5 population) 1
Targeted dosing – When deficiency is confirmed, prescribe B‑complex at approximately one Recommended Daily Allowance (RDA) rather than higher doses. (Deficient patients) 1
Avoid excessive dosing – High‑dose B‑vitamin regimens (several times above RDA) are discouraged because CKD patients lack normal renal excretion mechanisms, increasing the risk of toxicity. (CKD 5 patients) 1

Thiamine deficiency – Up to 24.7 % of hemodialysis patients exhibit thiamine deficiency, highlighting the need for routine screening in this subgroup. (Hemodialysis cohort) 4

All statements are derived from peer‑reviewed sources cited above and reflect current KDOQI guideline recommendations.